Skip to main content

January 16, 2017

U.S. Food and Drug Administration (FDA) Advisory

December 16, 2016: Chantix (varenicline) and Zyban (bupropion) External Web Site Policy: Based on an FDA review of a large clinical trial that FDA required the drug companies to conduct, FDA determined the risk of serious side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) is lower than previously suspected. The risk of these mental health side effects is still present, especially in those currently being treated for mental illnesses such as depression, anxiety disorders, or schizophrenia, or who have been treated for mental illnesses in the past. However, most people who had these side effects did not have serious consequences such as hospitalization. The results of the trial confirm that the benefits of stopping smoking outweigh the risks of these medicines.

Conference News

Registration is now open External Web Site Policy for the Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS III) Conference. It will be held March 20-21, 2017 at The New York Academy of Medicine. The event is sponsored by the Guidelines International Network North America (G-I-N NA) and NYAM's Section on Evidence Based Health Care (SEBHC). The conference is titled "Beyond Implementation: Are Clinical Guidelines Improving Healthcare Quality?"

AHRQ Announces Funding Opportunity for Developing Measures of Shared Decisionmaking

A new funding opportunity announcement External Web Site Policy from AHRQ solicits applications for research projects to develop, test and evaluate measures of shared decisionmaking for research conducted in clinical settings. Shared decisionmaking is a collaborative process in which patients and members of their clinical team make health care decisions that are informed by scientific evidence as well as patients' values and preferences. Each project is expected to produce valid and reliable measures of shared decisionmaking, along with instructions for implementing the measures and documentation on the development, testing and evaluation of the measures. The maximum cost for each project is $500,000 per year and $1.5 million for up to three years.

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.

Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC) External Web Site Policy.